Background: Patients with gastric cancers producing alpha-fetoprotein (AFP) were reported to have a poor prognosis with high rates of liver metastasis. The purpose of the present study was to clarify the clinicopathological features of AFP-producing gastric cancers, in particular characteristics of liver metastasis, and to evaluate treatment of these cancers. Methods: In 27 of the 29 cases with elevated preoperative serum AFP levels among a total of 974 primary gastric cancers, AFP production was confirmed in gastric cancer cells by immunohistochemistry. These cases were included in the AFP-positive gastric cancer group (AFP(+), 2.7%). The remaining 945 cases with normal serum AFP levels were designated the AFP-negative gastric cancer group (AFP(–)). Results: There was a higher incidence of lymph node metastasis, a deeper invasion of the gastric wall, a higher frequency of advanced stage, a more marked lymphatic invasion and a higher rate of liver metastasis in the AFP(+) group than in the AFP(–) group. The patients received curative resection in AFP(+) group had a significantly worse survival rates in comparison to that in AFP(–) group. With respect to liver metastasis (n = 17) in AFP(+) group, of 3 cases who received curative hepatic resection, 1 patient survived more than 3 years, while the remaining 2 died in less than 3 years due to multiple liver recurrence. The patients (n = 5) who received palliative resection for liver metastasis followed by transarterial continuous infusion chemotherapy all died in less than 1 year. Conclusion: AFP-producing gastric cancers had aggressive behavior and their clinical or biological features were quite different from the common AFP-negative gastric cancers. Surgical resection of liver metastasis from AFP-producing gastric cancers was unsatisfactory. The development of a novel multimodal therapy against AFP-producing gastric cancers is needed.

Keywords:
Alpha-fetoprotein, Gastric cancer, Liver metastasis
1.
Bergstrand CG, Czar D: Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 1956;8:174.
2.
Bourreille J, Metayer P, Sauger F, Matray F, Fondimare A: Existence d’alpha foetoprotéine au cours d’un cancer secondaire du foie d’origine gastrique. Presse Méd 1970;78:1277–1278.
3.
McIntire KR, Waldmann TA, Moertel CG, Go VL: Serum α-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res 1975;35:991–996
4.
Chang YC, Nagasue N, Abe S, Kohno H, Yamanoi A, Uchida M, Nakamura T: The characters of AFP-producing early gastric cancer. J Jpn Surg Soc 1990;91:1574–1580.
5.
Motoyama T, Aizawa K, Watanabe H, Fukase M, Saito K: α-Fetoprotein-producing gastric carcinomas: A comparative study of three different subtypes. Acta Pathol Jpn 1993;43:654–661.
6.
Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T: Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 1992;87:321–325.
7.
Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J: Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis and angiogenesis. Am J Gastroenterol 1999;94:1658–1663.
8.
Amemiya H, Kono K, Mori Y, Takahashi A, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y: High frequency of c-Met expression in gastric cancers producing α-fetoprotein. Oncology 2000;59:145–151.
9.
Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al: American Joint Committee on Cancer Staging Manual, ed 5. Philadelphia, Lippincott, 1997, pp 171–190.
10.
Sudo T, Tsutsui S, Ito M, Morita S, Sawai M: Immunochemical model for the agglutination reaction of FR antigens in a new latex photometric immunoassay with near infrared turbidimetry. Kitasato Arch Exp Med 1980;53:55–68.
11.
Matsumoto K, Nakamura T: Hepatocyte growth factor as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997;239:639–644.
12.
Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, Yoko K, White W, Cook C, Moellmann G: Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992;7:2195–2206.
13.
Tajima H, Matsumoto K, Nakamura T: Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 1992;202:423–431.
14.
Matsumoto K, Nakamura T: Hepatocyte growth factor: Molecular structure, roles in liver regeneration and other biological functions. Crit Rev Oncog 1992;3:27–54.
15.
Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate ML, Vaula G, Comoglio PM: c-Met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991;6:553–559.
16.
Kaji M, Yonemura Y, Harada S, Liu X, Terada I, Yamamoto H: Participation of c-Met in the progression of human gastric cancers: Anti-c-Met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 1996;3:393–404.
17.
Sato Y, Nishimaki T, Date K, Shirai Y, Kurosaki I, Saito Y, Wataname T, Hatakeyama K: Successful resection of metachronous liver metastasis from α-fetoprotein-producing gastric cancer. Surg Today 1999;29:1075–1078.
18.
Tsurumachi T, Yamamoto H, Watanabe K, Honda I, Watanabe S, Yamada S, Jingu K, Satomi D, Fujita M: Resection of liver metastasis from a-fetoprotein-producing early gastric cancer. Surg Today 1997;27:563–566.
19.
Tomiya T, Tani M, Yamada S, Hayashi S, Umeda N, Fujiwara K: Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology 1992;103:1621–1624.
20.
Kaneko A, Hayashi N, Tanaka Y, Ito T, Kasahara A, Kubo M, Mukata T, Fusamoto H, Kamada T: Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy. Am J Gastroenterol 1992;87:1014–1017.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.